Imaging studies in drug development: Parkinson's disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) can help confirm the diagnosis of parkinsonian disorders where this is in doubt and provide potential biomarkers for following the effects of putative neuroprotective and restorative agents on disease progression. PET can also establish that novel therapeutics reach their intended targets and generate dose-occupancy profiles. Finally, PET and SPECT can indirectly monitor changes in brain dopamine levels and so throw light on the pharmacology underlying treatment-associated complications.

Original languageEnglish
JournalDrug Discovery Today: Technologies
Pages (from-to)317-321
Number of pages5
Publication statusPublished - 1 Dec 2005
Externally publishedYes

See relations at Aarhus University Citationformats

ID: 131307326